INO
Price
$2.05
Change
+$0.01 (+0.49%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
75M
NVAX
Price
$6.61
Change
+$0.31 (+4.92%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
1.02B
36 days until earnings call
Interact to see
Advertisement

INO vs NVAX

Header iconINO vs NVAX Comparison
Open Charts INO vs NVAXBanner chart's image
Inovio Pharmaceuticals
Price$2.05
Change+$0.01 (+0.49%)
Volume$4.5K
Capitalization75M
Novavax
Price$6.61
Change+$0.31 (+4.92%)
Volume$52.85K
Capitalization1.02B
INO vs NVAX Comparison Chart in %
Loading...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INO vs. NVAX commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (INO: $2.04 vs. NVAX: $6.30)
Brand notoriety: INO and NVAX are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 130% vs. NVAX: 38%
Market capitalization -- INO: $75M vs. NVAX: $1.02B
INO [@Biotechnology] is valued at $75M. NVAX’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, NVAX is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 3 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, INO is a better buy in the short-term than NVAX.

Price Growth

INO (@Biotechnology) experienced а +5.44% price change this week, while NVAX (@Biotechnology) price change was -0.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

INO is expected to report earnings on May 13, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.02B) has a higher market cap than INO($75M). INO YTD gains are higher at: 14.326 vs. NVAX (-21.642). NVAX has higher annual earnings (EBITDA): 555M vs. INO (-93.37M). NVAX has more cash in the bank: 731M vs. INO (68.4M). INO has less debt than NVAX: INO (11.3M) vs NVAX (229M). NVAX has higher revenues than INO: NVAX (1.22B) vs INO (283K).
INONVAXINO / NVAX
Capitalization75M1.02B7%
EBITDA-93.37M555M-17%
Gain YTD14.326-21.642-66%
P/E RatioN/A2.29-
Revenue283K1.22B0%
Total Cash68.4M731M9%
Total Debt11.3M229M5%
FUNDAMENTALS RATINGS
INO vs NVAX: Fundamental Ratings
INO
NVAX
OUTLOOK RATING
1..100
6057
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5685
P/E GROWTH RATING
1..100
10050
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (57) in the Medical Specialties industry is in the same range as NVAX (87) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's Price Growth Rating (56) in the Medical Specialties industry is in the same range as NVAX (85) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for INO (100) in the Medical Specialties industry. This means that NVAX’s stock grew somewhat faster than INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INONVAX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSIAX45.90N/A
N/A
PGIM Quant Solutions Large-Cap Index A
HICVX22.07N/A
N/A
Hennessy Cornerstone Value Inst
MMUCX23.60N/A
N/A
MFS Utilities C
JDVVX23.85N/A
N/A
JHancock Disciplined Value R5
GAGAX33.81N/A
N/A
Gabelli Global Rising Income and Div A

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-3.55%
RPTX - INO
58%
Loosely correlated
N/A
BCYC - INO
55%
Loosely correlated
-4.01%
AXON - INO
53%
Loosely correlated
+1.14%
ARRY - INO
52%
Loosely correlated
-8.39%
ONCO - INO
50%
Loosely correlated
-1.24%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.10%
MRNA - NVAX
46%
Loosely correlated
+1.58%
ARCT - NVAX
43%
Loosely correlated
-2.40%
THRD - NVAX
42%
Loosely correlated
N/A
BNTX - NVAX
41%
Loosely correlated
-0.23%
CRSP - NVAX
39%
Loosely correlated
+4.15%
More